Johnson & Johnson Announce Booster Shot Improves Immunity Two Months After First Dose

The Daily Caller

Johnson & Johnson announced Tuesday that its second dose of the COVID-19 vaccine increases protection by 94% after two months of receiving the initial shot.

The Phase 3 study found that Johnson & Johnson’s two-month booster shot gives 100% protection against severe cases of COVID-19, and 94% against moderate symptomatic cases in the U.S., according to a company press release. The current single-dose vaccine is 75% effective.

“Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations. Additionally, our Phase 3 trial data further confirm protection against COVID-19-related death,” Mathai Mammen, global head of research and development at Johnson and Johnson, said in the press release.

In January, the pharmaceutical giant announced that trials showed the single dose of its COVID-19 vaccine was 66% effective against severe cases of the disease, according to The Wall Street Journal.


Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster.

“Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations. Additionally, our Phase 3 trial data further confirm protection against COVID-19-related death,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”

“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19. A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”

The Company has provided available data to the U.S. Food and Drug Administration (FDA) and plans to submit the data to other regulators, the World Health Organization (WHO) and National Immunization Technical Advisory Groups (NITAGs) worldwide to inform decision-making on local vaccine administration strategies, as needed.

Johnson and Johnson Press Release

“We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly,” Paul Stoffels, chief scientific officer at Johnson and Johnson, said in the press release.

The side effects of the booster are reported to be similar to those experienced with the single shot, according to the press release. Johnson & Johnson’s vaccine is currently the only single-shot jab offered in the U.S., while Pfizer and Moderna require two does.

Johnson & Johnson’s announcement comes after the Food and Drug Administration voted against approving Pfizer’s COVID-19 booster shot for U.S. citizens ages 16 and older. The panel approved the third shot for adults over the age of 65.

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact  licensing@dailycallernewsfoundation.org. Read the full story at the Daily Caller News Foundation

 

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.